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This activity is available for CME credit. See page A3 for information.Introduction: It is recommended that all pregnant women in the U.S. receive tetanus, diphtheria, acellular 
pertussis (Tdap) immunization to prevent infant pertussis. This study’s objective  was to examine  the clinical  
effectiveness of prenatal Tdap, and whether effectiveness varies by gestational age at immunization.
Methods: A nationwide cohort study of pregnant women with deliveries in 2010–2014 and their infants 
was performed. Commercial insurance claims data were analyzed in 2016–2017 to identify Tdap receipt by 
the pregnant women, and hospitalizations and outpatient visits for pertussis in their infants until the infants 
reached 18 months of age. Pertussis occurrence was compared between infants of mothers who received 
prenatal Tdap (overall and stratified by gestational age at administration) and infants of unvaccinated 
mothers.
Results: There were 675,167 mother–infant pairs in the cohort. Among infants whose mothers 
received prenatal Tdap, the rate of pertussis was 43% lower (hazard ratio¼0.57, 95% CI¼0.35, 0.92) 
than infants whose mothers did not receive prenatal or postpartum Tdap; this reduction was 
consistent across pertussis definitions (hazard ratio for inpatient-only pertussis¼0.32, 95% CI¼0.11, 
0.91). Pertussis rates were also lower for infants whose mothers received Tdap during the third 
trimester. Infants whose mothers received Tdap at o27 weeks of gestation did not experience 
reductions in pertussis rates (hazard ratio for pertussis¼1.10, 95% CI¼0.54, 2.25).
Conclusions: Infants of mothers who received prenatal Tdap experienced half the rate of pertussis as 
compared with infants of unimmunized mothers. These results do not provide evidence to support 
changing the currently recommended timing of Tdap administration in pregnancy.
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i.org/10.1016/j.amepre.2018.04.013Pertussis, or respiratory infection caused by Bordetellapertussis, has been rising in incidence in the U.S. since2000.1 In 2015, there were 20,762 pertussis cases
reported to the National Notifiable Diseases Surveillance
System, with an annual incidence rate of 99/100,000 in
infants under age 6 months.1 Disease in infants is more
likely to be severe and result in hospitalization,2,3 apnea, and
pneumonia.4,5 Most concerning, infants accounted for
between 50% and 92% of all pertussis-related deaths.1
To reduce the burden of pertussis in children, the
Centers for Disease Control and Prevention (CDC)
recommends that all infants receive the primary series of
diphtheria, tetanus, acellular pertussis (DTaP) at ages 2,
4, and 6 months, with booster doses at ages 15–18
months and 4–6 years. However, maximal protection is
typically not attained until after the third dose of the
vaccine at age 6 months,6,7 leaving young infants at
higher risk of pertussis. Additional CDC recommenda-
tions have been made in recent years, including the
provision of a booster dose of tetanus, diphtheria,
acellular pertussis (Tdap) to adolescents and Tdap
immunization of close adult and adolescent contacts of
infants.8,9 These strategies have had limited success in
decreasing rates of infant pertussis. Therefore, in 2011,
the CDC recommended that pregnant women who
previously had not received Tdap receive a one-time
Tdap booster in pregnancy to provide passive immunity
to their infants through transplacental antibody transfer.9
New immunogenicity data following the recommenda-
tion showed that anti-pertussis antibodies are short-lived
and mothers immunized before the current pregnancy or
in early pregnancy may have insufficient pertussis-
specific antibodies to protect their infants against infec-
tion.10 Subsequently, the CDC recommended the provi-
sion of Tdap in each pregnancy, with the optimal timing
of administration at 27–36 weeks of gestation.11
The optimal timing of Tdap immunization during
pregnancy is currently under dispute. It is unclear if Tdap
immunization in the second trimester of pregnancy
could result in increased protection as compared with
the third trimester, the currently recommended optimal
timing.12,13 The CDC recommendations for Tdap during
pregnancy and its optimal timing were primarily
informed by immunologic studies; limited clinical effi-
cacy data exist on the best timing of Tdap administration
during pregnancy. Another important concern is
whether passively acquired maternal antibodies may
blunt the infant’s active immune response to the primary
series of DTaP, potentially leaving infants at higher risk
for pertussis once passively acquired antibodies wane
over time. This concern is based on immunologic studies
showing that infants whose mothers received Tdap
during pregnancy or whose mothers had high titers of
anti-pertussis antibodies had weaker antibody responses
to pertussis antigens following the primary DTaP ser-
ies.14,15 The clinical significance of these immunologic
findings is not known.
The goal of this study is to determine the clinical
effectiveness of prenatal Tdap in the prevention of infant
pertussis, and to understand if effectiveness varies by gesta-
tional age at Tdap administration. Further, the study
examines rates of pertussis after the age of 6 months (the
recommended age at primary DTaP series completion), to
determine whether the immunologic finding of blunting bymaternal antibodies has clinical relevance. If findings show
that Tdap in pregnancy is highly effective at preventing infant
pertussis, this may improve acceptability and uptake of the
vaccine in pregnant women.METHODS
Data Sample
An observational cohort of pregnant women and their infants (defined
here as ager18 months ) delivered between June 2010 and December
2014 was constructed using the Truven Health Analytics Market-
Scans Commercial Claims and Encounters Databases (copyright©
2016 Truven Health Analytics Inc., all rights reserved), which contains
insurance enrollment and billing data for commercially insured
employees, spouses, and dependents from ffi100 large employers
around the U.S.16 These databases include billed, adjudicated, and paid
insurance claims for inpatient and outpatient health facility visits,
procedures, and their associated diagnosis codes; outpatient claims for
medications filled by pharmacies; and claims for performing laboratory
tests, but they do not include linkage back to the medical record to
access the results of laboratory tests. Mothers with delivery claims
(ICD-9-CM codes V27.0–V27.6) were linked within family enrollment
groupings to newborns covered on the same insurance plan with birth
codes (ICD-9-CM codes V30–V37) occurring within 30 days of the
mother’s delivery codes (to allow variation in the beginning of infant
enrollment). Infants covered under insurance plans different from the
mothers’ would be unable to match. Enrollment was restricted to the
first delivery per woman occurring between June 2010 and December
2014, and to those with singleton deliveries occurring 426 weeks of
gestational age. Time periods prior to the recommendation were
included to provide a better comparison group of unvaccinated women
to avoid solely comparing recommendation-compliant women with
noncompliant women after the recommendations were given, which
could potentially introduce confounding by access or attitudes to health
care. Methods used for estimating gestational age at delivery and
vaccination have been described previously.17 In brief, the hierarchical
algorithm estimated gestational age based on diagnosis and procedure
codes assigned to the mother and infant related to pre-maturity, post-
maturity, and gestational length. Continuous insurance enrollment was
required for mothers from estimated pregnancy onset to 7 days post-
delivery to fully characterize maternal characteristics and vaccination
status, and for infants until 7 days post-delivery. Infants were followed
until censoring at the first occurrence of either the end of follow-up (6
months or 18 months, depending on the analysis) or the end of the
study period (December 31, 2014), or disenrollment in the insurance
claims database. Clinical and demographic characteristics were col-
lected using diagnosis, procedure, and medication claims and enroll-
ment information. Potential confounding variables, including
demographic and clinical characteristics, were identified from the
mothers during pregnancy and delivery, and from the infants at
delivery and during the first 7 days, prior to the beginning of follow-up.Measures
Maternal Tdap immunization was identified through procedure
codes (Current Procedural Terminology code 90715, ICD-9-CM
99.37, 99.39) from estimated pregnancy onset until 7 days post-
delivery, with the administration timing categorized as prenatal
(from pregnancy onset to 2 weeks prior to delivery—also stratified
o27 weeks, or Z27 weeks to 2 weeks prior to delivery) or
postpartum (from 2 weeks prior to delivery to 7 days post-
delivery). Mothers vaccinated in the 2 weeks prior to delivery were
categorized as postpartum, as it takes approximately 2 weeks for
the full immune response to the vaccine; in these cases, the mother
would be most similar to mothers who have received Tdap
vaccination in the postpartum period.
Infants were followed from day 7 post-delivery up to age 18
months for evidence of pertussis. As laboratory test results are not
contained in the claims databases, three different claims-based
pertussis definitions were employed, relying on submitted diag-
noses, tests ordered, and antibiotics dispensed, as follows:1. Pertussis, the primary outcome, included either an inpatient
pertussis diagnosis alone or an outpatient pertussis diagnosis
plus antibiotic treatment with azithromycin, clarithromycin,
erythromycin, or trimethoprim/sulfamethoxazole within 7
days. In the outpatient setting, the results of laboratory testing
may not be accessible to the treating physician at the time the
diagnosis code is assigned on the insurance claim. Therefore,
the requirement for an appropriate antibiotic claim was added
to outpatient pertussis visit claims to increase the specificity of
the outpatient pertussis diagnosis.2. Inpatient-only pertussis included only inpatient pertussis
diagnoses. This is likely the most specific of the three
definitions, as diagnosis codes for hospital claims are assigned
on hospital discharge; laboratory tests performed during the
hospitalization would commonly be completed prior to patient
discharge, and therefore, the hospital physician would have this
information prior to assigning a diagnosis code for the
hospitalization.3. Possible pertussis includes both definitions above, and also
includes outpatient visits with a diagnosis of cough, plus a
claim for a pertussis laboratory test, and antibiotic treatment
with a macrolide or trimethoprim/sulfamethoxazole within 7
days. This is the broadest of the three definitions and includes
the scenario where the provider suspects pertussis in the
outpatient setting but may not yet have laboratory results to
support the diagnosis.Statistical Analysis
Associations of prenatal (overall and stratified by timing) and 
postpartum maternal immunization with infant pertussis were 
assessed by estimating hazard ratios (HRs) and 95% CIs using a 
multivariable Cox proportional hazards model, using monthly 
intervals. HRs were adjusted for demographic and clinical char-
acteristics of the mother and infant. Season and cumulative 
number of infant DTaP doses received were included as monthly 
time-varying covariates in the Cox model.18 Complete case 
analysis was performed, where infants with missing covariates 
were excluded from the multivariable analysis. To assess associa-
tions of maternal immunization with outcomes both before and 
after the recommended age for completion of the infant’s primary 
DTaP series, infant follow-up was stratified into two windows: 7 
days to 6 months, and 6 to 18 months. Final multivariable models 
were adjusted for infant’s sex, year of delivery, number of infant 
DTaP doses received (time-varying, monthly), season (time-
varying, monthly), residence in a metropolitan statistical area 
(binary, as a measure of urbanicity), U.S. region, other childrencovered on insurance plan (categorized as zero, one, two or more),
premature birth, stay in the neonatal intensive care unit
during the first week of life, and maternal age. A sensitivity
analysis limited to infants aged o2 months was also performed.
Analyses were performed in 2016–2017 using SAS, version 9.4.
This study was approved by the IRB of the University of North
Carolina at Chapel Hill.
RESULTS
Among 1,079,034 pregnant women with live-born deliv-
eries who met eligibility criteria between 2010 and 2014,
a total of 675,167 (62.6%) were successfully matched to a
newborn. These 675,167 infants contributed a total of
672,497 person-years of follow-up time; on average, each
infant contributed 355 days (SD¼191 days). Baseline
characteristics of mother–infant pairs are shown in
Table 1. Characteristics of mothers who were matched
to newborns were similar to the overall sample of
mothers (Appendix Table 1, available online).
Over the time period studied, 90,445 (13.4%) women
received prenatal Tdap (were vaccinated during preg-
nancy 42 weeks prior to delivery). There were 5,872
(0.9%) women vaccinated in the 2 weeks prior to delivery
and were included in the postpartum Tdap group, along
with 36,470 (5.4%) women who received the vaccine on
the day of delivery or in the 7 days after delivery. Among
infants whose mothers received prenatal Tdap, the rate of
pertussis was 43% lower (HR¼0.57, 95% CI¼0.35, 0.92),
and the rate of inpatient-only pertussis was 68% lower
(HR¼0.32, 95% CI¼0.11, 0.91) than infants whose
mothers did not receive prenatal or postpartum Tdap
(Table 2). When evaluating prenatal Tdap effectiveness
by timing of immunization, infants whose mothers
received prenatal Tdap at Z27 weeks experienced lower
rates of pertussis compared with infants of unimmunized
mothers (HR¼0.42, 95% CI¼0.23, 0.78, for pertussis and
HR¼0.30, 95% CI¼0.09, 0.97, for inpatient-only pertus-
sis). Infants whose mothers received Tdap at o27 weeks
did not experience reductions in pertussis rates
(HR¼1.10, 95% CI¼ 0.54, 2.25). Although these infants
tended to have lower rates of pertussis hospitalizations
and possible pertussis (Table 2), inferences were impre-
cise because of limited numbers of mothers receiving
Tdap at o27 weeks. Similarly, infants whose mothers
received Tdap in the postpartum period tended to have
lower pertussis rates compared with infants whose
mothers did not receive Tdap, but inferences were
imprecise.
The majority of pertussis cases occurred in the first 6
months of life (Table 3). During this time, infants whose
mothers received prenatal Tdap had a 46% lower rate of
pertussis (HR¼0.54, 95% CI¼0.31, 0.94), and a 75%
lower rate of inpatient-only pertussis (HR¼0.25, 95%


















30.3 (4.6) 30.4 (4.5) 30.5 (4.4) 30.1 (4.4) 30.2 (4.6)
Infant sex
Male 344,010 (51.0) 8,225 (50.5) 37,603 (50.7) 21,583 (51.0) 276,599 (51.0)
Female 331,157 (49.1) 8,048 (49.5) 36,569 (49.3) 20,759 (49.0) 265,781 (49.0)
Birth year
2010 112,093 (16.6) 225 (1.4) 398 (0.5) 3,503 (8.3) 107,967 (19.9)
2011 152,179 (22.5) 1,402 (8.6) 1,132 (1.5) 9,968 (23.5) 139,677 (25.8)
2012 161,932 (24.0) 3,117 (19.2) 6,894 (9.3) 12,290 (29.0) 139,631 (25.7)
2013 115,563 (17.1) 5,011 (30.8) 20,685 (27.9) 8,057 (19.0) 81,810 (15.1)
2014 133,400 (19.8) 6,518 (40.1) 45,063 (60.8) 8,524 (20.1) 73,295 (13.5)
U.S. regiond
Northeast 110,444 (16.4) 2,403 (14.8) 11,293 (15.2) 5,863 (13.9) 90,885 (16.8)
Midwest 179,380 (26.6) 4,269 (26.2) 21,696 (29.3) 10,321 (24.4) 143,094 (26.4)
South 241,110 (35.7) 4,482 (27.5) 21,544 (29.1) 16,388 (38.7) 198,696 (36.6)
West 130,787 (19.4) 4,664 (28.7) 17,522 (23.6) 8,882 (21.0) 99,719 (18.4)
Lives in MSA 586,911 (86.9) 14,419 (88.6) 65,771 (88.7) 36,965 (87.2) 469,789 (86.6)
Received obstetric
blood panele
382,611 (56.7) 9,347 (57.4) 42,134 (56.8) 26,507 (62.6) 304,623 (56.2)
Received ultrasounde 551,774 (81.7) 15,014 (92.3) 66,612 (89.8) 36,147 (85.4) 434,001 (80.0)
Received influenza
vaccine
158,179 (23.4) 8,468 (52.0) 36,162 (48.8) 10,735 (25.4) 102,814 (19.0)
Hospitalizations,
mean (SD)e
0.008 (0.098) 0.006 (0.092) 0.005 (0.081) 0.008 (0.100) 0.008 (0.101)
Maternal
hypertension
92,897 (13.8) 2,279 (14.0) 10,315 (13.9) 5,949 (14.1) 74,354 (13.7)
Gestational diabetes 99,473 (14.7) 2,404 (14.8) 11,358 (15.3) 6,485 (15.3) 79,226 (14.6)
Preterm delivery 50,338 (7.5) 1,697 (10.4) 3,530 (4.8) 3,498 (8.3) 41,613 (7.7)
Delivered by
cesarean section




1.9 (1.0) 1.7 (0.9) 1.7 (0.9) 1.8 (1.0) 1.9 (1.0)
Received all DTaP on
timef
496,789 (73.6) 13,077 (80.4) 62,479 (84.2) 32,891 (77.7) 388,342 (71.6)
Total follow-up in
study, person-years
672,497 14,122 52,364 39,840 566,172
aVaccinated after 27 weeks’ gestational age but prior to 2 weeks before delivery.
bVaccinated in the 2 weeks prior to delivery, on the day of delivery, or in the 7 days after delivery.
cUnvaccinated during pregnancy or in the postpartum period.
dPercentages do not add up to 100% because of missing data.
eAssessed from pregnancy onset to 20 weeks of gestation.
fOn-time defined as not more than 1 month late for any DTaP vaccine, according to Centers for Disease Control and Prevention (CDC) recommended
schedule, by the end of the follow-up period.
DTaP, diphtheria, tetanus, acellular pertussis immunization; MSA, metropolitan statistical area or group of counties containing at least one urbanized
area that has a population of at least 50,000; Tdap, tetanus, diphtheria, acellular pertussis immunization.CI¼0.08, 0.80), as compared with infants whose mothers
did not receive prenatal or postpartum Tdap. A sensi-
tivity analysis limited to infants agedo2 months showed
similar HR estimates as for those aged o6 months, but
because of the smaller number of cases, estimates for
those agedo2 months had wider CIs (Appendix Table 2,available online). Between 6 and 18 months of life, there
were no differences in pertussis rates by receipt of
prenatal Tdap after adjustment for the infant’s DTaP
receipt (HR¼0.69, 95% CI¼0.26, 1.86, for pertussis and
HR¼2.60, 95% CI¼0.15, 46.2, for inpatient-only
pertussis).
Tdap status n Cases (%) Crude HR (95% CI) Adjusted HR (95% CI)
Any prenatal Tdapa versus no Tdapb
Pertussis
No Tdap 542,380 403 (0.07) – –
Any prenatal Tdap 90,445 32 (0.04) 0.51 (0.32, 0.80) 0.57 (0.35, 0.92)
Inpatient-only pertussis
No Tdap 542,380 151 (0.03) – –
Any prenatal Tdap 90,445 7 (0.01) 0.25 (0.09, 0.67) 0.32 (0.11, 0.91)
Possible pertussis
No Tdap 542,380 919 (0.17) – –
Any prenatal Tdap 90,445 65 (0.07) 0.58 (0.43, 0.79) 0.73 (0.53, 1.01)
Prenatal Tdap Z27 weeksc versus no Tdap
Pertussis
No Tdap 542,380 403 (0.07) – –
Prenatal Z27 weeks 74,172 22 (0.03) 0.38 (0.21, 0.67) 0.42 (0.23, 0.78)
Inpatient-only pertussis
No Tdap 542,380 151 (0.03) – –
Prenatal Z27 weeks 74,172 5 (0.01) 0.23 (0.07, 0.72) 0.30 (0.09, 0.97)
Possible pertussis
No Tdap 542,380 919 (0.17) – –
Prenatal Z27 weeks 74,172 49 (0.07) 0.56 (0.40, 0.79) 0.71 (0.49, 1.02)
Prenatal Tdap o27 weeks versus no Tdap
Pertussis
No Tdap 542,380 403 (0.07) – –
Prenatal o27 weeks 16,273 10 (0.06) 1.03 (0.51, 2.07) 1.10 (0.54, 2.25)
Inpatient-only pertussis
No Tdap 542,380 151 (0.03) – –
Prenatal o27 weeks 16,273 2 (0.01) 0.33 (0.05, 2.36) 0.38 (0.05, 2.74)
Possible pertussis
No Tdap 542,380 919 (0.17) – –
Prenatal o27 weeks 16,273 16 (0.10) 0.67 (0.37, 1.22) 0.82 (0.45, 1.49)
Postpartum Tdapd versus no Tdap
Pertussis
No Tdap 542,380 403 (0.07) – –
Postpartum 42,342 24 (0.06) 0.76 (0.46, 1.25) 0.80 (0.48, 1.32)
Inpatient-only pertussis
No Tdap 542,380 151 (0.03) – –
Postpartum 42,342 11 (0.0) 0.87 (0.41, 1.87) 0.92 (0.43, 1.99)
Possible pertussis
No Tdap 542,380 919 (0.17) – –
Postpartum 42,342 61 (0.14) 0.80 (0.58, 1.12) 0.83 (0.59, 1.16)
Note: Models were adjusted for infant’s sex; year of delivery; number of infant diphtheria, tetanus, acellular pertussis (DTaP) doses received (time-
varying, monthly); season (time-varying, monthly); residence in a metropolitan statistical area (binary, as a measure of urbanicity); U.S. region; other
children covered on insurance plan (categorized as 0, 1, Z2); premature birth; stay in the neonatal intensive care unit during the first week of life;
maternal age.
aVaccinated after estimated onset of pregnancy but prior to 2 weeks before delivery.
bUnvaccinated during pregnancy or in the postpartum period.
cVaccinated after 27 weeks’ gestational age but prior to 2 weeks before delivery.
dVaccinated in the 2 weeks prior to delivery, on the day of delivery, or in the 7 days after delivery.
HR, hazard ratio; Tdap, tetanus-diphtheria-acellular pertussis immunization.
Table 2. Rates of Pertussis up to Age 18 months by Receipt and Timing of Maternal TdapDISCUSSION
This study compared clinical outcomes of 675,167 
privately insured U.S. infants by maternal Tdapimmunization status. Infants whose mothers received
Tdap immunization during pregnancy experienced about
half the rate of pertussis as compared with infants whose
Table 3. Rates of Pertussis by Receipt of Prenatal Tdap, Stratified by Infant Age
Tdap status n Cases(%) Crude HR (95% CI) Adjusted HR (95% CI)
Age 7 days to 6 months
Pertussis
No Tdapa 542,380 310 (0.06) – –
Any prenatalb 90,445 22 (0.03) 0.45 (0.27, 0.76) 0.54 (0.31, 0.94)
Inpatient-only pertussis
No Tdap 542,380 145 (0.03) – –
Any prenatal 90,445 6 (0.01) 0.19 (0.06, 0.60) 0.25 (0.08, 0.80)
Possible pertussis
No Tdap 542,380 419 (0.08) – –
Any prenatal 90,445 30 (0.03) 0.51 (0.34, 0.79) 0.65 (0.41, 1.02)
Age 6 months to 18 months
Pertussis
No Tdap 422,214 87 (0.02) – –
Any prenatal 53,508 10 (0.02) 0.85 (0.34, 2.12) 0.69 (0.26, 1.86)
Inpatient-only pertussis
No Tdap 422,214 6 (0.00) – –
Any prenatal 53,508 1 (0.00) 2.97 (0.31, 28.6) 2.60 (0.15, 46.2)
Possible pertussis
No Tdap 422,214 468 (0.11) – –
Any prenatal 53,508 35 (0.07) 0.70 (0.46, 1.08) 0.86 (0.54, 1.37)
Note: Models were adjusted for infant’s sex; year of delivery; number of infant diphtheria, tetanus, acellular pertussis (DTaP) doses received (time-
varying, monthly); season (time-varying, monthly); residence in a metropolitan statistical area (binary, as a measure of urbanicity); U.S. region; other
children covered on insurance plan (categorized as 0, 1, Z2); premature birth; stay in the neonatal intensive care unit during the first week of life;
maternal age.
aUnvaccinated during pregnancy or in the postpartum period.
bVaccinated after estimated onset of pregnancy but prior to 2 weeks before delivery.
HR, hazard ratio; Tdap, tetanus-diphtheria-acellular pertussis immunization.mothers did not receive it during pregnancy or in the
postpartum period. This study adds to two prior studies
from the United Kingdom that showed high effectiveness
(approximately 90%) of prenatal Tdap in infants under
age 3 months.19,20 A study from six U.S. Emerging
Infection Program Network states reported an effective-
ness of 78% during the first 2 months of life,21 whereas
another study in the Kaiser Permanente population in
California reported an effectiveness of 69% during the
first year of life.22 The estimates of the benefit of prenatal
Tdap in this study, which followed infants up to age 18
months, were weaker than in these previous studies,
which examined infants over shorter time intervals.
These differences may be because of duration of protec-
tion afforded by maternal Tdap immunization. The half-
life of transplacental anti-pertussis antibodies is approx-
imately 7 weeks23; therefore, the benefits of maternal
immunization diminish over time. A sensitivity analysis
did not show greater protection of prenatal Tdap for
infants during the first 2 months of life as compared with
the first 6 months of life, but these estimates became
imprecise.
In the analyses of timing of vaccination, infants whose
mothers received prenatal Tdap during the third trimesterexperienced reductions in pertussis cases and hospitalizations
as compared with infants of unimmunized mothers. The
study did not find statistically significant reductions of infant
pertussis rates in mothers who were immunized before the
third trimester or in the postpartum period. Therefore, these
data do not provide evidence to support a change in the
current recommendation for optimal timing of immuniza-
tion. There may be logistic reasons to recommend Tdap
vaccination earlier in pregnancy, such as to provide protec-
tion to infants born prematurely; future studies should
examine the overall risks and benefits to the population of
such a strategy. Further, there was no evidence for an
increase in pertussis rates after the typical age of DTaP
primary series completion for infants of immunized mothers
compared with infants of unimmunized mothers, to provide
clinical relevance to the finding that maternal antibodies may
interfere with the infant’s response to the primary DTaP
series.14,15 However, overall numbers of pertussis cases in
older infants used in these comparisons were small.
Limitations
There are limitations of claims-based analyses, including the
possibility of misclassification. Three definitions of pertussis
were employed. Although inpatient diagnoses may be the
 most specific, as discharge diagnoses  are likely made after the
results of microbiology laboratory tests are available, many 
pertussis cases are assessed and treated in the outpatient 
setting, where diagnosis coding may be based on symptoms 
rather than confirmed diagnoses, as laboratory results are 
likely not available during the outpatient visit. Using 
combinations of pertussis diagnosis codes, more general 
symptom codes, laboratory testing, and antibiotic treatment 
coding, three levels of pertussis were defined from confirmed 
inpatient cases to potential cases. Analyses were performed 
using all three definitions, and the conclusions were con-
sistent across the pertussis definitions.
Also, although insurance plan enrollment is grouped 
by families, there is not a direct link identifying the 
resulting offspring from a woman’s delivery within the 
insurance claims. Mother–infant matchings were based 
on family grouping and delivery/birth date, but there 
remains the potential for matching errors, potentially 
resulting in misclassification of maternal Tdap exposure 
in newborns. It is unlikely that matching errors would 
differ by Tdap status, and any resulting nondifferential 
misclassification would likely bias the results towards 
the null, thus not explaining the observed protective 
associations.
In addition, estimates for early immunization were 
imprecise as the majority of women received the vaccine 
after 27 weeks of gestational age. Finally, this study was 
restricted to a privately insured population and may not 
be generalizable to publicly or uninsured populations. 
The strengths of the study include a large sample size 
from a variety of healthcare settings throughout the U.S., 
and accurate assessment of exposure, as insurance claims 
are audited and serve as the basis for reimbursement.24
CONCLUSIONS
Prenatal Tdap provided a substantial reduction in infant 
pertussis during the period of life with the highest 
pertussis burden. Increasing use of Tdap in pregnancy 
would be anticipated to reverse the current trends of 
pertussis incidence among infants in the U.S.ACKNOWLEDGMENTS
This work was supported by the National Institute of Allergy and 
Infectious Diseases (5R21AI115205). The database infrastruc-
ture used for this project was funded by the Department of 
Epidemiology, University of North Carolina (UNC) Gillings School 
of Global Public Health; the Cecil G. Sheps Center for Health 
Services Research, UNC; the Comparative Effectiveness 
Research Strategic Initiative of UNC’s Clinical & Translational 
Science Award (UL1TR001111); and the UNC School of Medi-
cine. Dr. Becker-Dreps is supported by Grant 2015213 from the 
Doris Duke Charitable Foundation. The study sponsors had norole in the study design; data collection, analysis, and inter-
pretation; manuscript preparation; or the decision to submit the
report for publication. This study was approved by the IRB of the
UNC at Chapel Hill (FWA No.: 4801, Study No.: 13-3679).
Dr. Butler performed this work when she was at the UNC at
Chapel Hill.
Author tasks were as follows: conception of the study: SBD,
LJM, KAB, DJW, and MGH; data analysis: SBD, AMB, DL, MGH,
and JBL; interpretation: SBD, AMB, LJM, KAB, DJW, MGH, and
JBL; completed first draft of manuscript: SBD, AMB, and JBL;
and reviewed, revised for intellectual content, and approved
manuscript: all authors.
Dr. Becker-Dreps received investigator-initiated research
funds from Pfizer for a study on pneumococcal vaccines and
served as a vaccine consultant (Pfizer). Dr. Butler received
investigator-initiated research funds from Amgen, Inc.
Dr. Weber served on speakers’ bureaus and as a vaccine
consultant (Merck, Pfizer). Dr. Layton is a current employee of
RTI International, an independent research organization that
does contract work for governmental agencies and pharma-
ceutical companies; he is formerly an employee of UNC,
where he received unrestricted salary support from the UNC
Center for Pharmacoepidemiology, whose current members
include GlaxoSmithKline, Merck, and UCB Biosciences. Drs.
McGrath, Boggess, and Hudgens and Ms. Li have no financial
disclosures.SUPPLEMENTAL MATERIAL
Supplemental materials associated with this article can be
found in the online version at https://doi.org/10.1016/j.
amepre.2018.04.013.REFERENCES
1. Centers for Disease Control and Prevention (CDC). Pertussis: surveil-
lance and reporting, 2012–2016. www.cdc.gov/pertussis/surv-report
ing.html. Accessed August 23, 2017.
2. Cortese MM, Baughman AL, Zhang R, et al. Pertussis hospitalizations
among infants in the United States, 1993 to 2004. Pediatrics. 2008;121
(3):484–492. https://doi.org/10.1542/peds.2007-1393.
3. Miller CL, FletcherWB. Severity of notified whooping cough. Br Med J.
1976;1(6002):117–119. https://doi.org/10.1136/bmj.1.6002.117.
4. Eidlitz-Markus T, Mimouni M, Zeharia A. Pertussis symptoms in
adolescents and children versus infants: the influence of vaccination
and age. Clin Pediatr (Phila). 2007;46(8):718–723. https://doi.org/
10.1177/0009922807302093.
5. Gordon M, Davies HD, Gold R. Clinical and microbiologic features of
children presenting with pertussis to a Canadian pediatric hospital
during an eleven-year period. Pediatr Infect Dis J. 1994;13(7):617–622.
https://doi.org/10.1097/00006454-199407000-00007.
6. Auerbach BS, Lake AM, Wilson ME, et al. Dose-response to a two-
component acellular pertussis vaccine in infants and comparison with
whole-cell vaccine. Biologicals. 1998;26(2):145–153. https://doi.org/
10.1006/biol.1998.9999.
7. Bisgard KM, Rhodes P, Connelly BL, et al. Pertussis vaccine effectiveness
among children 6 to 59 months of age in the United States, 1998–2001.
Pediatrics. 2005;116(2):e285–e294. https://doi.org/10.1542/peds.2004-2759.
8. Broder KR, Cortese MM, Iskander JK, et al. Preventing tetanus,
diphtheria, and pertussis among adolescents: use of tetanus toxoid,
reduced diphtheria toxoid and acellular pertussis vaccines
recommendations of the Advisory Committee on Immunization
Practices (ACIP). MMWR Recomm Rep. 2006;55(RR-3):1–34.
9. Centers for Disease Control and Prevention (CDC). Updated recom-
mendations for use of tetanus toxoid, reduced diphtheria toxoid and
acellular pertussis vaccine (Tdap) in pregnant women and persons who
have or anticipate having close contact with an infant aged 12 months
– Advisory Committee on Immunization Practices (ACIP), 2011.
MMWR Morb Mortal Wkly Rep. 2011;60(41):1424–1426.
10. Healy CM, Rench MA, Baker CJ. Importance of timing of maternal
combined tetanus, diphtheria, and acellular pertussis (Tdap) immuni-
zation and protection of young infants. Clin Infect Dis. 2013;56(4):539–
544. https://doi.org/10.1093/cid/cis923.
11. Centers for Disease Control and Prevention (CDC). Updated recom-
mendations for use of tetanus toxoid, reduced diphtheria toxoid, and
acellular pertussis vaccine (Tdap) in pregnant women—Advisory
Committee on Immunization Practices (ACIP), 2012. MMWR Morb
Mortal Wkly Rep. 2013;62(7):131–135.
12. Eberhardt CS, Blanchard-Rohner G, Lemaitre B, et al. Maternal
immunization earlier in pregnancy maximizes antibody transfer and
expected infant seropositivity against pertussis. Clin Infect Dis. 2016;62
(7):829–836. https://doi.org/10.1093/cid/ciw027.
13. Abu Raya B, Srugo I, Kessel A, et al. The effect of timing ofmaternal tetanus,
diphtheria, and acellular pertussis (Tdap) immunization during pregnancy
on newborn pertussis antibody levels—a prospective study.Vaccine. 2014;32
(44):5787–5793. https://doi.org/10.1016/j.vaccine.2014.08.038.
14. Hardy-Fairbanks AJ, Pan SJ, Decker MD, et al. Immune responses in
infants whose mothers received Tdap vaccine during pregnancy.
Pediatr Infect Dis J. 2013;32(11):1257–1260. https://doi.org/10.1097/
INF.0b013e3182a09b6a.
15. Voysey M, Kelly DF, Fanshawe TR, et al. The influence of maternally
derived antibody and infant age at vaccination on infant vaccine
responses: an individual participant meta-analysis. JAMA Pediatr.
2017;171(7):637–646. https://doi.org/10.1001/jamapediatrics.2017.0638.16. MarketScan Database. MarketScan User Guide, Commercial Claims
and Encounters, Medicare Supplemental and Coordination of Benefits.
Ann Arbor, MI: Thomson Reuters (Healthcare) Inc.; 2008.
17. Butler AM, Layton JB, Li D, et al. Predictors of low uptake of prenatal
tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis
immunization in privately insured women in the United States. Obstet
Gynecol. 2017;129(4):629–637. https://doi.org/10.1097/AOG.00000-
00000001927.
18. Powell TM, Bagnell ME, editors. Your “survival” guide to using time-
dependent covariates. SAS Global Forum 2012. http://support.sas.com/
resources/papers/proceedings12/168-2012.pdf. Accessed August 29, 2017.
19. Amirthalingam G, Andrews N, Campbell H, et al. Effectiveness
of maternal pertussis vaccination in England: an observational
study. Lancet. 2014;384(9953):1521–1528. https://doi.org/10.1016/
S0140-6736(14)60686-3.
20. Dabrera G, Amirthalingam G, Andrews N, et al. A case-control study
to estimate the effectiveness of maternal pertussis vaccination in
protecting newborn infants in England and Wales, 2012–2013. Clin
Infect Dis. 2015;60(3):333–337. https://doi.org/10.1093/cid/ciu821.
21. Skoff TH, Blain AE, Watt J, et al. Impact of the U.S. maternal tetanus,
diphtheria, and acellular pertussis vaccination program on preventing
pertussis in infants 2 months of age: a case-control evaluation. Clin
Infect Dis. 2017;65(12):1977–1983. https://doi.org/10.1093/cid/cix724.
22. Baxter R, Bartlett J, Fireman B, et al. Effectiveness of vaccination
during pregnancy to prevent infant pertussis. Pediatrics. 2017;139(5).
https://doi.org/10.1542/peds.2016-4091.
23. Vilajeliu A, Ferrer L, Munros J, et al. Pertussis vaccination during
pregnancy: Antibody persistence in infants. Vaccine. 2016;34(33):
3719–3722. https://doi.org/10.1016/j.vaccine.2016.05.051.
24. Schneeweiss S, Avorn J. A review of uses of health care utilization
databases for epidemiologic research on therapeutics. J Clin
Epidemiol. 2005;58(4):323–337. https://doi.org/10.1016/j.jclinepi.2004.
10.012.
